Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (NCT07352566)
Utilization of a Cutaneous Therapy In Situ Microdevice
🩺 Plain-English Summary (8th-Grade Level)
This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis. The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.
Who can join: Review the eligibility criteria below.
Location: University of California, San Francisco — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
- In situ cutaneous microdevice (DEVICE)
- Triamcinolone (DRUG)
- 5-Fluorouracil (DRUG)
- Calcipotriene (DRUG)
- Tapinarof (DRUG)
- Crisaborole (DRUG)
- Tacrolimus (DRUG)
- Adalimumab (DRUG)
- Etanercept (DRUG)
- Certolizumab (DRUG)
- Infliximab (DRUG)
- Secukinumab (DRUG)
- Ixekizumab (DRUG)
- Apremilast (DRUG)
- Risankizumab (DRUG)
- Ustekinumab (DRUG)
- Hydroxychloroquine (DRUG)
- Methotrexate (DRUG)
- Mycophenolate (DRUG)
- Azathioprine (DRUG)
- Chloroquine (DRUG)
- Cyclosporine (DRUG)
- Tofacitinib (DRUG)
- Deucravacitinib (DRUG)
- Dupilumab (DRUG)
- Tralokinumab (DRUG)
- Guselkumab (DRUG)
- Tildrakizumab (DRUG)
- Baractinib (DRUG)
- Abrocitinib (DRUG)
- Upadacitinib (DRUG)
- Lebrikizumab (DRUG)
- Nemolizumab (DRUG)
- Ruxolitinib (DRUG)
- Bimekizumab (DRUG)
- Roflumilast (DRUG)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of California, San Francisco — San Francisco, California
📞 Contact the Study Coordinator
Phone: (415) 353-7800
Email: raymond.cho@ucsf.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Psoriasis
- Deucravacitinib Adherence Study — Winston-Salem, North Carolina
- An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects — San Diego, California
- Psoriasis Longitudinal Assessment and Registry — Birmingham, Alabama
- Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 — Birmingham, Alabama
- Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis — Birmingham, Alabama
- Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis — Scottsdale, Arizona
Explore by condition: All Psoriasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.